Pharsight

1. Xpovio patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9714226	KARYOPHARM THERAPS	Hydrazide containing nuclear transport modulators and uses thereof	Jul, 2032 (8 years from now)
US8999996	KARYOPHARM THERAPS	Hydrazide containing nuclear transport modulators and uses thereof	Jul, 2033 (9 years from now)
US10519139	KARYOPHARM THERAPS	Polymorphs of Selinexor	Aug, 2035 (11 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9079865	KARYOPHARM THERAPS	Hydrazide containing nuclear transport modulators and uses thereof	Jul, 2032 (8 years from now)
US10544108	KARYOPHARM THERAPS	Hydrazide containing nuclear transport modulators and uses thereof	Jul, 2032 (8 years from now)
US11034660	KARYOPHARM THERAPS	Hydrazide containing nuclear transport modulators and uses thereof	Jul, 2032 (8 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
ODE* (ODE*)	Jul 3, 2026
Orphan Drug Exclusivity (ODE)	Dec 18, 2027
New Chemical Entity Exclusivity (NCE)	Jul 3, 2024
New Indication (I)	Jun 22, 2023

Drugs and Companies using SELINEXOR ingredient

NCE-1 date: 2023-07-04

Market Authorisation Date: 03 July, 2019

Treatment: Xpovio is indicated in combination with dexamethasone to treat relapsed or refractory multiple myeloma (refractory to at least an anti-cd38 mab, 2 proteasome inhibitors and 2 immunomodulatory agents) ...

Dosage: TABLET;ORAL